Anti CD47 Drugs Market Outlook: Growth, Trends, Forecast The anti CD47 drugs industry is experiencing an inflection driven by breakthroughs in macrophage-mediated immunotherapy and strategic biomarker integration. Detailed market insights indicate that robust business growth and evolving industry trends are reshaping treatment paradigms for hematologic and solid tumor segments. Advanced clinical pipelines and expanded market research are fueling an aggressive market growth trajectory around the globe. Market Size and Overview The anti CD47 drugs market is estimated to be valued at USD 0.20 Bn in 2025 and is expected to reach USD 2.46 Bn by 2032, growing at a compound annual growth rate (CAGR) of 43.1% from 2025 to 2032. Recent Anti CD47 Drugs Market report underscores expanding industry size and industry share potential, fueled by high unmet need in defined market segments. This jump in market revenue reflects growing market opportunities across hematologic malignancies and solid tumors, even as market challenges around safety profiles are addressed via adaptive designs. The market forecast further highlights robust business growth driven by combination regimen market trends. Use Case Scenarios As per the latest market report and market analysis, several high-impact implementation cases have emerged: • Bristol Myers Squibb’s BMS-986012 combination trial in AML (Q3 2024) delivered a 30% complete remission rate, aligning with Anti CD47 Drugs Market trends toward personalized regimens and showcasing a key market driver. • ALX Oncology’s ALX148 plus pembrolizumab pilot in metastatic solid tumors achieved a 25% PFS improvement in early 2025, demonstrating seamless integration benefits in core market segments. • Innovent Biologics reported a 40% tumor reduction with IBI188 in non-Hodgkin’s lymphoma (H2 2024), highlighting market opportunities identified in recent market analysis. Policy and Regulatory Impact • In March 2025, the US FDA granted Orphan Drug Designation for BMS-986012, streamlining approval and mitigating key market restraints related to clinical trial costs. • July 2024’s EMA guidance update on immuno-oncology combinations broadened Anti CD47 Drugs Market share potential in Europe, recalibrating market dynamics under international standards. • China’s NMPA priority review pathway for novel biologics (Dec 2024) reduced entry barriers and expanded market scope, bolstering business growth across the Asia-Pacific region. Key Market Players • Bristol Myers Squibb • ALX Oncology • Trillium Therapeutics • Innovent Biologics • Forty Seven (Gilead Sciences) • Merck & Co. • Roche • Novartis • Amgen • Pfizer • Johnson & Johnson • AstraZeneca These market companies are vying for leadership in immuno-oncology. ‣ Anti CD47 Drugs Market: https://www.coherentmi.com/industry-reports/anti-cd47-drugs-market